Income StatementBalance SheetCash FlowSegments
Medtronic logo

Medtronic Cash Flow Statement

Operating, investing, and financing cash movements

Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$7.1BNet Cash From Investing (TTM)-$2.4BNet Cash From Financing (TTM)-$5.0BCapital Expenditures (TTM)$1.8BDepreciation And Amortization Cf (TTM)$2.9BNet Change In Cash (TTM)-$38.0M
Latest FilingQ1 2026
Report Date2026-02-24
Market Cap$100.91B
P/E Ratio21.88
ROE9.38%

Operating

MetricQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Other non-cash income (expense)-$176.0M—-$296.0M-$159.0M——
Change in accounts payable-$176.0M$623.0M$366.0M-$598.0M——
Change in inventories$455.0M——$373.0M——
Other working capital changes$997.0M——$464.0M——
Change in receivables$36.0M$258.0M$249.0M-$288.0M——
Benefit from Receivables$48.0M$30.0M$27.0M$28.0M——
Deferred income taxes$72.0M-$241.0M-$235.0M$167.0M——
Depreciation and amortization$831.0M$528.0M$840.0M$748.0M——
Impairment charges$0.0$0.0$0.0———
Other Non-Cash Income (Expense)-$176.0M—-$296.0M-$159.0M——
Other Non-cash Income (Expense)-$176.0M—-$296.0M-$159.0M——
Other Non-cash Income (Expense)-$176.0M—-$296.0M-$159.0M——
Net cash from operating activities$1.0B$2.5B$2.5B$1.1B——
Net income$1.3B$1.3B$1.1B$1.0B$1.4B$1.2B
Other non-cash income (expense)-$176.0M—-$296.0M-$159.0M——
Asset write-downs$0.0$0.0$0.0———
Increase (Decrease) in Accounts and Notes Receivable$36.0M$258.0M$249.0M-$288.0M——
Other Noncash Income (Expense)-$176.0M—-$296.0M-$159.0M——
Accounts Receivable, Credit Loss Expense (Reversal)$48.0M$30.0M$27.0M$28.0M——
Other Non-cash Income and Expense-$176.0M—-$296.0M-$159.0M——
Other Non-Cash Adjustments-$176.0M—-$296.0M-$159.0M——
Other Non-Cash Income and Expense-$176.0M—-$296.0M-$159.0M——
Provision for credit losses$48.0M$30.0M$27.0M$28.0M——
Stock-based compensation$185.0M$72.0M$89.0M$86.0M——

Investing

MetricQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Acquisitions, net of cash acquired$24.5M$24.5M$24.5M———
Capital expenditures$452.0M$428.0M$459.0M$504.0M——
Payment for (Proceeds from) Other Investing Activity-$31.0M$125.0M$138.0M$125.0M——
Proceeds from disposition of marketable securities and other investments$1.8B$2.3B$2.2B$2.0B——
Net cash from investing activities-$942.0M-$246.0M-$490.0M-$719.0M——
Other investing activities-$31.0M$125.0M$138.0M$125.0M——
Proceeds from maturities/sales of investments$1.8B$2.3B$2.2B$2.0B——
Purchases of investments$2.3B$1.9B$2.1B$2.1B——

Financing

MetricQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Proceeds from issuance of debt—$1.5B—$0.0——
Repayments of debt$2.9B-$2.9B$0.0$1.2B——
Dividends paid$922.0M$872.0M$897.0M$910.0M——
Proceeds from issuance of shares$166.0M$145.0M$108.0M$95.0M——
Other, net$80.0M$31.0M-$280.0M$70.0M——
Short-term borrowings/(repayments) less than 90 days — net$2.0B-$2.5B$0.0$649.0M——
Repayments of Short-Term Debt$0.0$0.0$0.0———
Payment of Deferred Purchase Consideration$80.0M$31.0M-$280.0M$70.0M——
Noncontrolling interest transactions and other$80.0M$31.0M-$280.0M$70.0M——
Net cash from financing activities-$1.0B-$1.2B-$1.3B-$1.4B——
Other financing activities$80.0M$31.0M-$280.0M$70.0M——
Noncontrolling Interests Activity and Other$80.0M$31.0M-$280.0M$70.0M——
Proceeds from issuance of common stock$166.0M$145.0M$108.0M$95.0M——
Repurchases of common stock—$2.5B$274.0M$123.0M——
Net change in short-term borrowings$2.0B-$2.5B$0.0$649.0M——

Free Cash Flow

MetricQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Free cash flow$575.0M$2.1B$2.1B$584.0M——

Other

MetricQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Effect of exchange rate changes on cash$0.0-$123.0M$283.0M$67.0M——
Net increase (decrease) in cash-$963.0M$892.0M$978.0M-$945.0M——

Supplemental

MetricQ2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Income taxes paid$1.0B$121.0M$304.0M$402.0M——
Interest paid$423.0M$25.0M$195.0M$81.0M——
Income Taxes Paid, Net$1.0B$121.0M$304.0M$402.0M——